Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading Volume

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) saw strong trading volume on Tuesday . 1,116,913 shares changed hands during trading, a decline of 1% from the previous session’s volume of 1,129,558 shares.The stock last traded at $25.30 and had previously closed at $25.28.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Jefferies Financial Group restated a “hold” rating and issued a $25.60 price target (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday. JMP Securities reaffirmed a “market perform” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday. Stifel Nicolaus lifted their price target on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. upped their price objective on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Finally, Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.17.

Deciphera Pharmaceuticals Stock Up 0.4 %

The company has a 50 day moving average of $16.18 and a 200 day moving average of $14.63.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. The firm had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.60) earnings per share. Equities analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Deerfield Management Company L.P. Series C increased its position in Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after purchasing an additional 190,580 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Deciphera Pharmaceuticals by 36.7% in the 3rd quarter. Deutsche Bank AG now owns 254,671 shares of the company’s stock valued at $3,239,000 after buying an additional 68,435 shares during the period. Panagora Asset Management Inc. acquired a new stake in shares of Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,167,000. Dark Forest Capital Management LP raised its position in shares of Deciphera Pharmaceuticals by 18.9% during the 3rd quarter. Dark Forest Capital Management LP now owns 60,216 shares of the company’s stock valued at $766,000 after buying an additional 9,553 shares during the period. Finally, Diversified Trust Co acquired a new position in Deciphera Pharmaceuticals in the fourth quarter valued at approximately $193,000. Institutional investors and hedge funds own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.